前列舒通联合塞来昔布治疗Ⅲ型慢性前列腺炎疼痛患者的临床研究  

Clinical study of Qianlieshutong combined with celecoxib in the treatment ofⅢtype chronic prostatitis pain patients

作　　者：洪志明[1,2] 陈子龙 王胜杰 陈君其 王全[2] 曾杨玲 邱俊峰 翁浩伟 蔡俊平 HONG Zhiming;CHEN Zilong;WANG Shengjie;CHEN Junqi;WANG Quan;ZENG Yangling;QIU Junfeng;WENG Haowei;CAI Junping(Department of Andrology,the Fourth Clinical Medical College of Guangzhou University of Traditional Chinese Medicine,Shenzhen 518033,Guangdong,China;Department of Andrology,Shenzhen Traditional Chinese Medicine Hospital,Shenzhen 518033,Guangdong,China;Guangzhou University of Traditional Chinese Medicine,Guangzhou 510006,Guangdong,China)

机构地区：[1]广州中医药大学第四临床医学院男科,广东深圳518033 [2]深圳市中医院男科,广东深圳518033 [3]广州中医药大学,广州510006

出　　处：《中国性科学》2023年第4期17-21,共5页Chinese Journal of Human Sexuality

基　　金：深圳市中医重点专科建设项目(2019-2023年)。

摘　　要：目的探讨前列舒通联合塞来昔布治疗Ⅲ型慢性前列腺炎(CP)疼痛患者的疗效及安全性。方法选取2020年6月至2021年6月深圳市中医院男科门诊诊治的120例Ⅲ型CP疼痛患者作为研究对象。采用区组随机化法分成A组(n=40)、B组(n=40)和C组(n=40)。A组口服前列舒通胶囊,B组口服塞来昔布胶囊,C组口服前列舒通胶囊联合塞来昔布胶囊。比较三组治疗后的慢性前列腺炎症状评分表(NIH-CPSI)评分、疼痛症状评分、治疗有效率和血清炎性因子水平。结果治疗后,C组总有效率显著高于A组和B组,NIH-CPSI及疼痛症状评分显著低于A组和B组(P<0.05);治疗后,A组和C组的肿瘤坏死因子-α及环氧化酶-2水平均明显低于B组,白介素-10水平明显高于B组(P<0.05)。结论前列舒通联合塞来昔布治疗Ⅲ型CP疼痛患者的临床疗效显著,作用机制可能与前列舒通能降低前列腺中肿瘤坏死因子-α及环氧化酶-2水平,同时提升白介素-10水平有关。Objective To investigate the efficacy and safety of Qianlieshutong combined with celecoxib in the treatment ofⅢtype chronic prostatitis(CP)pain patients.Methods 120 patients with typeⅢCP pain diagnosed and treated in the Andrology Clinic of Shenzhen Traditional Chinese Medicine Hospital from June 2020 to June 2021 were selected as the research objects.They were divided into group A(n=40),group B(n=40)and group C(n=40)by block randomization.Group A was given Qianlieshutong capsule orally,group B was given celecoxib capsule orally,and group C took Qianlieshutong capsule combined with celecoxib capsule orally.The National Institute of Health-chronic prostatitis symptom index(NIH-CPSI)score,pain symptom score,treatment effectiveness and serum inflammatory factor levels were compared among the three groups after treatment.Results After treatment,the total effective rate of group C was significantly higher than that of group A and group B,and the NIH-CPSI and pain symptom scores were significantly lower than those of group A and group B(P<0.05).After treatment,the levels of tumor necrosis factor-αand cyclooxygenase-2 in group A and group C were significantly lower than those in group B,and the level of interleukin-10 were significantly higher than that in group B(P<0.05).Conclusions Qianlieshutong combined with celecoxib has a significant clinical effect in the treatment of patients with typeⅢCP pain,and the mechanism of action may be related to the fact that Qianlieshutong can reduce tumor necrosis factor-αand cyclooxygenase-2 in the prostate while increasing the level of interleukin-10.

关 键 词：前列舒通胶囊 塞来昔布胶囊 慢性前列腺炎 炎性因子 

分 类 号：R697[医药卫生—泌尿科学]